Journal of Clinical and Experimental Ophthalmology
Open Access
ISSN: 2155-9570
+44 1223 790975
ISSN: 2155-9570
+44 1223 790975
Gary C Brown
Center for Value-Based Medicine®, Hilton Head, SC, Wills Eye Hospital,
Philadelphia, Pennsylvania
Tanzania
Research Article
Combination Therapy with Dietary Zeaxanthin for Neovascular Age Related Macular Degeneration. A Randomized Clinical Trial
Author(s): R Joseph Olk, Enrique Peralta, Dennis L Gierhart, Melissa M Brown and Gary C BrownR Joseph Olk, Enrique Peralta, Dennis L Gierhart, Melissa M Brown and Gary C Brown
Purpose: A previous comparative interventional study suggested oral zeaxanthin added to triple therapy of intravitreal bevacizumab, intravitreal corticosteroids and photodynamic therapy with verteporfin for the treatment of neovascular age-related macular degeneration (NVAMD) was comparatively effective and cost-effective. A randomized clinical trial was undertaken to confirm these effects.
Methodology: A two-year, triple-blinded, randomized clinical trial enrolled 144 participants (168 eyes) with NVAMD to triple therapy (TT) (intravitreal bevacizumab, reduced-fluence photodynamic therapy and intravitreal dexamethasone) or the same triple therapy with oral zeaxanthin (TTZ) supplementation, 20 mg daily. Data were modeled out to the 11-year life expectancy of the average participant.
Results: At 24-months, twenty-sev.. View More»
DOI:
10.4172/2155-9570.1000692